江苏德源药业股份有限公司（以下简称"公司"）分别于 2024 年 3 月 28 日、2024 年 4 月 23 日召开了第四届董事会第四次会议、2023 年年度股东大会， 审议通过了《关于公司续聘会计师事务所的议案》，同意聘请天健会计师事务所 （特殊普通合伙）为公司 2024 年度审计机构，聘期 1 年。 近日，公司收到天健会计师事务所（特殊普通合伙）出具的《关于变更签字 注册会计师的函》，现将具体情况公告如下： 一、签字会计师变更情况 天健会计师事务所（特殊普通合伙）原指派王福康先生、张军燕女士作为公 司2024年度财务报表审计报告和2024年末财务报告内部控制审计报告的签字注 册会计师。鉴于原签字注册会计师张军燕女士工作调整，现委派方磊女士接替张 军燕女士作为签字注册会计师继续完成相关工作。变更后的签字注册会计师为： 王福康、方磊。 二、本次变更签字注册会计师简历及独立性和诚信情况 方磊女士 2019 年 4 月成为中国注册会计师，自 2019 年 4 月开始在天健会计 证券代码：832735 证券简称：德源药业 公告编号：2024-073 江苏德源药业股份有限公司 关于变更签字注册会计师的公告 本公司及 ...

证券代码：832735 证券简称：德源药业 公告编号：2024-072 江苏德源药业股份有限公司 投资者关系活动记录表 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 (投资者线上交流会) 二、 投资者关系活动情况 活动时间：2024 年 8 月 29 日至 2024 年 8 月 30 日 活动地点：线上交流会 参会单位及人员：开源证券、浙商证券、国元证券、渤海证券、申万宏源证 券、第一创业证券、财信证券、国泰基金、中天汇富基金、华夏养老、呈瑞投资、 新威投资、拓朴私募、懿德投资、广汇缘资产、临信资产、九祥资产、汇瑾资产、 青骊泰川、荷荷私募、中信证券、海通证券。（排名不分先后） 上 ...

Investment Rating - The investment rating for the company is "Outperform" (Maintain) [1] Core Insights - The company reported a revenue of 432 million yuan for H1 2024, representing a year-on-year increase of 19.35%, and a net profit attributable to shareholders of 80.19 million yuan, up 11.56% year-on-year [1] - The growth is driven by the diabetes and hypertension segments, with a notable increase in R&D expenses by 70% in H1 2024, indicating a strong focus on innovation and new product development [2] - The company has adjusted its profit forecasts for 2024-2026, now expecting net profits of 158 million yuan, 187 million yuan, and 202 million yuan respectively, with corresponding EPS of 2.02, 2.39, and 2.58 yuan per share [1][3] Financial Performance Summary - For H1 2024, the company achieved a revenue of 432 million yuan, with a year-on-year growth of 19% [1] - The net profit attributable to shareholders for H1 2024 was 80.19 million yuan, reflecting a year-on-year increase of 12% [1] - The company’s R&D expenses reached 64.85 million yuan in H1 2024, accounting for 15% of revenue, indicating a significant investment in future growth [2] - The company’s revenue from diabetes products was 294 million yuan, up 14.25% year-on-year, while hypertension products saw a revenue increase of 29.89% [2] - The company’s projected financial metrics for 2024E include a revenue of 823 million yuan and a net profit of 158 million yuan, with a gross margin of 81.7% and a net margin of 19.2% [3][5]

证券代码：832735 证券简称：德源药业 公告编号：2024-071 江苏德源药业股份有限公司 股权激励计划限制性股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 本次股票解除限售数量总额为 876,600 股，占公司总股本 1.1203%，可交易 时间为 2024 年 9 月 5 日。 二、本次股票解除限售的明细情况及原因 单位：股 | | | 是否为 | | 本 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 控股股 | 董事、监 | 次 | 本次解 | 本次变 | | 本次解除 | 尚未解 | | | 股东姓 | 东、实 | 事、高级 | 解 | | 更限售 | | | | | 序 | 名或名 | 际控制 | 管理人 | 限 | 除限售 | 类型登 | 变更后限 | 限售股数 | 除限售 | | 号 | | | | | 登记股 | | 售类型 | 占公司总 | 的 ...

证券代码：832735 证券简称：德源药业 公告编号：2024-070 √是 □否 江苏德源药业股份有限公司 持股 5%以上股东减持股份结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 减持主体减持前基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 徐维钰 | 持股 | 5%以上 | 4,473,477 | 5.72% | 上市前取得和上市后二级市场 | | | 股东 | | | | 竞价取得（含权益分派转增股） | 二、 减持计划的实施结果 （一） 股东因以下原因披露减持计划实施结果： √减持计划实施完毕 □减持时间区间届满 | 股 | 已减持 | 已减 | | | | | 减持 | 当前持 | 当前 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 东 | | | 减持 | ...

Company Overview - Jiangsu Deyuan Pharmaceutical Co., Ltd. received drug registration certificates for several products, including Febuxostat tablets and Metformin Empagliflozin tablets, indicating successful compliance with consistency evaluation[3]. - The company operates in the pharmaceutical manufacturing industry, specifically in the production of chemical drug formulations[13]. - The company is listed on the Beijing Stock Exchange since November 15, 2021, under the stock code 832735[13]. - The actual controllers of the company are natural person shareholders, including Li Yong'an and Chen Xueming, ensuring stable management[13]. - The company has not faced any delisting risks, as confirmed in the risk assessment section of the report[8]. Financial Performance - The company's operating revenue for the current period reached ¥432,481,805.86, representing a year-on-year increase of 19.35% compared to ¥362,366,758.41 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was ¥80,194,053.71, reflecting an 11.56% increase from ¥71,881,427.38 in the previous year[17]. - The total assets at the end of the period amounted to ¥1,224,475,185.82, which is a 6.09% increase from ¥1,154,156,478.60 at the end of the previous year[18]. - The total liabilities increased by 8.66% to ¥223,627,503.60 from ¥205,806,841.21 in the previous year[18]. - The company maintained a gross profit margin of 84.59%, up from 82.18% in the same period last year[17]. - The net cash flow from operating activities decreased by 36.68% to ¥35,153,121.29 from ¥55,512,455.70 in the previous year[19]. Research and Development - The company invested 64.86 million yuan in R&D during the first half of 2024, representing a 69.74% increase year-on-year, accounting for 15.00% of operating revenue[28]. - The company has obtained a total of 21 authorized patents, including 16 invention patents, indicating a strong commitment to R&D[22]. - The company plans to expand its product pipeline in chronic diseases and metabolic syndrome treatments, continuing to develop products for diabetes complications and other related areas[22]. - The company is developing a new Class 1 drug, DYX116, which has completed preclinical research[30]. - The company is transitioning from a focus on generic drugs to a combination of generics and innovative drugs, aiming to enhance its product pipeline and address chronic diseases, metabolic diseases, and geriatric diseases[54]. Market and Sales Strategy - The major products include Pioglitazone Metformin tablets and Canagliflozin tablets, among others, indicating a diverse product portfolio in the pharmaceutical sector[13]. - The sales strategy includes dynamic management of distribution partners, focusing on those with strong capabilities and creditworthiness[24]. - The company plans to launch a new product, "非布司他片" (Febuxostat), on January 30, 2024, which is expected to enhance the product line and optimize the product structure[42]. - The sales revenue from diabetes products increased by 14.25%, with the product "复瑞彤" (Pioglitazone Metformin Tablets) showing a 24.95% increase in sales revenue compared to the previous year[42]. Environmental and Quality Management - The company emphasizes product quality, achieving a 100% pass rate in quality inspections according to GMP standards[50]. - The company has implemented an environmental monitoring plan in accordance with pollution discharge permits, ensuring that all waste gas and wastewater meet discharge standards[51]. - The company has established a comprehensive emergency response plan for environmental incidents, including regular training for employees[51]. - The company has invested in advanced pollution control facilities, including a fully enclosed clean workshop for solid preparation processes[51]. Corporate Governance - The company has a dedicated board secretary, Wang Qibing, who can be contacted for further inquiries[11]. - The company has appointed a new board of directors and senior management team effective December 1, 2023, with terms lasting until November 30, 2026[71]. - The company has implemented a restricted stock incentive plan to motivate and retain key employees, ensuring alignment with its strategic goals[55]. - The company’s independent directors hold no shares, indicating a separation from management ownership[73]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[6]. - The company acknowledges the risks associated with the supply of raw materials, which are essential for its products, and is focused on ensuring stable and cost-effective sourcing[55]. - The company has implemented measures to mitigate risks related to raw material price fluctuations, including diversifying suppliers and establishing long-term strategic partnerships[5]. Shareholder Information - The company reported a total share capital of 78,245,040 shares, with no preferred shares issued[13]. - The total number of unrestricted shares increased from 50,256,228 to 68,294,887, representing a rise from 64.23% to 87.28% of total shares[65]. - The total shares held by the top ten shareholders is 45,207,077, accounting for 57.78% of the total shares[66]. - The company raised a total of 308.67 million CNY from public offerings, with a net amount of 284.19 million CNY after deducting issuance costs[69]. Financial Position - Cash and cash equivalents at the end of the reporting period amounted to CNY 30,514.62 million, a decrease of 32.74% compared to the previous year, primarily due to the investment in bank wealth management products[35]. - Accounts receivable increased by 49.74% to CNY 6,545.45 million, driven by steady growth in sales revenue and an increase in bank acceptance bills received[35]. - The company reported a significant increase in other non-current assets by 12,478.61% to CNY 3,199.54 million, primarily due to the purchase of long-term large-denomination bank certificates[35]. - The company’s total liabilities and equity at the end of the period were not specified but are critical for assessing financial health[155].

证券代码：832735 证券简称：德源药业 公告编号：2024-069 2024 年上半年募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏德源药业股份有限公司 截至 2023 年 12 月 31 日，公司使用募集资金 18,432.59 万元，其中发行费用 2,447.18 万元，原料药和制剂生产综合基地项目一期工程 7,930.96 万元，研发中心 建设项目785.67万元，药品研发项目1,754.38万元，超募资金补充流动资金5,514.40 万元，其中超募补流使用的资金中包含超募资金利息收入扣除银行手续费的净额 94.97 万元。 2、募集资金报告期内使用金额 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 2021 年 1 月 21 日，江苏德源药业股份有限公司（以下简称"公司"、"德源 药业"）收到中国证监会下发的《关于核准江苏德源药业股份有限公司向不特定 合格投资者公开发行股票的批复》（证监许可[2021]182 号），核准公司向不特定合 ...

证券代码：832735 证券简称：德源药业 公告编号：2024-065 江苏德源药业股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 8 月 27 日 2.会议召开地点：江苏省连云港经济技术开发区长江路 29 号公司三楼会议室 3.会议召开方式：现场和通讯相结合 4.发出董事会会议通知的时间和方式：2024 年 8 月 16 日以电子邮件方式发出 5.会议主持人：董事长陈学民 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次董事会会议的召集和召开符合《中华人民共和国公司法》《中华人民共和国 证券法》等法律法规以及《江苏德源药业股份有限公司章程》《江苏德源药业股份有 限公司董事会议事规则》等相关规定，会议的表决程序和表决结果合法有效。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事贾鹏、王玉春、周建平、周伟澄因工作原因 ...

证券代码：832735 证券简称：德源药业 公告编号：2024-066 江苏德源药业股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 8 月 27 日 2.会议召开地点：江苏省连云港经济技术开发区长江路 29 号公司三楼会议室 3.会议召开方式：现场会议 （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 1.议案内容： 1 / 2 公 司 2024 年 半 年 度 报 告 及 其 摘 要 刊 登 在 北 京 证 券 交 易 所 网 站 （www.bse.cn），公告编号分别为：2024-067 和 2024-068。 与会监事对董事会编制的 2024 年半年度报告及其摘要进行了认真审核，一 致认为： 4.发出监事会会议通知的时间和方式：2024 年 8 月 16 日以电子邮件方式发出 5.会议主持人：监事会主席何建忠 6.召开情况合法、合规、合章程性说明： 本次监事会会 ...

证券代码：832735 证券简称：德源药业 公告编号：2024-064 江苏德源药业股份有限公司 关于减少注册资本通知债权人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、通知债权人的原由 江苏德源药业股份有限公司（以下简称"公司"）于 2024 年 7 月 26 日分别 召开了第四届董事会第六次会议、第四届监事会第五次会议，审议通过了《关于 回购注销 2021 年限制性股票激励计划部分限制性股票的议案》。 根据《北京证券交易所股票上市规则（试行）》《北京证券交易所上市公司持 续监管指引第 3 号——股权激励和员工持股计划》及《江苏德源药业股份有限公 司章程》等相关法律法规、规范性文件以及《江苏德源药业股份有限公司 2021 年限制性股票激励计划（草案）》等相关规定，公司董事会在 2021 年第一次临时 股东大会的授权下，对 2023 年个人绩效考核结果"不合格"的 4 名激励对象和 3 名离职激励对象调整后持有已获授但尚未解除限售的限制性股票 34,380 股予 以回购注销，注销完成后公司 ...